MedImmune’s Mott heads for the exit; Italian regulators suspended in scandal;

> David Mott, the CEO of MedImmune who led his company through a $15.6 billion buyout by AstraZeneca, is leaving the company a year after the deal closed. Report

> The director of Italy's medicines regulatory agency has been suspended along with another top official, as the drug licences-for-cash scandal surrounding the organisation continues to unfold. Report

> Fresh from losing an insurgent attack aimed at winning back control of Biovail, Canadian entrepreneur Eugene Melnyk says he plans to invest $50 million to $100 million of his own money to start a new R&D focused development company--Trimel Pharmaceuticals. Report

> A South Korean patent court ruled in favour of five local pharmaceutical companies involved in a Lipitor patent dispute with Pfizer. Report

> Bayer won a court ruling that an Abbott Laboratories patent covering glucose-testing products isn’t enforceable, because Abbott's lawyer used deception to get the patent in the first place. Report

> Bristol-Myers Squibb wrapped up its tender offer for Kosan Biosciences. Report

> Daiichi Sankyo has decided to buy back a maximum of 15 million, or about 2 percent, of the company's outstanding ordinary shares for a total acquisition price of up to 50 billion yen. Report

> AstraZeneca refused to rule out a possible relocation of its headquarters to reduce the impact of taxes paid to the UK. Report

> Belgian healthcare group UCB expects to launch its new epilepsy drug Vimpat early in the fourth quarter, pending final European approval. Report

> Sinclair Pharma signed its first marketing distribution agreement in India with Wockhardt for a range of its oral and dermatology products. Release

> After a two-year run, pharmaceutical giant Wyeth is parting ways with Publicis Groupe's Kaplan Thaler Group, placing creative duties on the $55 million marketing account for its Centrum brand into review. Report

> Ruti Alon, general partner of Pitango Venture Capital, says the Israeli government will need to invest a significant amount of capital in its biotech industry if the industry intends to achieve its full potential in the field. Report

> Arizona officials have always talked an ambitious game plan for fostering its fledgling biotech sector. Now a biotechnology incubator and life sciences association in Arizona has launched the ThirdBiotech Research Group. Report

And Finally... Merck and Schering-Plough are ending their respiratory joint venture and their eight-year effort to market a combination of their Claritin and Singulair medications, which are used to treat allergic rhinitis. Report

Suggested Articles

Mylan and Pfizer's Upjohn have a name for their pending merger: Viatris. Heard that before? So has Mylan, which owns a subsidiary with the same name.

Intercept presented a data analysis that found treatment with Ocaliva led to "early and consistent improvements" in a range of noninvasive tests.

Days before Amarin faces a pivotal FDA vote on its Vascepa expansion, advisors are set to scrutinize the placebo used in its pivotal outcomes trial.